Zimmer Biomet (ZBH) Stock Price, News & Analysis

Company Overview

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a global leader in musculoskeletal healthcare, specializing in the design, manufacture and marketing of orthopedic reconstructive products, sports medicine, biologics, spinal and trauma devices, and dental implants. The company’s portfolio addresses a broad range of conditions affecting bones, joints and soft tissue, offering solutions intended to improve patient mobility and quality of life. Zimmer Biomet’s offerings span from joint replacement systems to surgical support products and bone cement, catering to the needs of healthcare professionals worldwide.

Formed through the 2015 merger of Zimmer Holdings, Inc. (founded in 1927) and Biomet, Inc. (founded in 1977), Zimmer Biomet is headquartered in Warsaw, Indiana, often referred to as the “Orthopedic Capital of the World.” Under the leadership of President and Chief Executive Officer Bryan Hanson, the company has continued to pursue innovation in musculoskeletal care and expand its product lines through strategic acquisitions and internal research and development efforts.

The company’s product suite includes hip, knee, shoulder and elbow replacement systems, trauma fixation devices, dental and craniomaxillofacial implants, and spinal technologies. Zimmer Biomet also invests in digital surgery, personalized implant solutions and robotic-assisted platforms to enhance surgical precision and outcomes. By integrating advanced imaging, surgical planning software and navigation tools, the company aims to deliver comprehensive treatment solutions across the continuum of care.

Zimmer Biomet operates in more than 100 countries, with manufacturing and research facilities located in North America, Europe, Asia and Latin America. The company serves hospitals, ambulatory surgery centers and dental practices, forging partnerships with healthcare providers to address the evolving needs of patients and clinicians. With a focus on global reach and local engagement, Zimmer Biomet continues to pursue opportunities in emerging markets while reinforcing its position in established healthcare systems.

Key Stats

• Today's Range: $93.25 to $95.95
• 50-Day Range: $90.22 to $98.18
• 52-Week Range: $89.22 to $116.71
• Volume: 2.35 million shs
• Average Volume: 1.82 million shs
• Market Capitalization: $18.60 billion
• P/E Ratio: 20.79
• Dividend Yield: 1.02%
• Price Target: $111.39
• Consensus Rating: Hold

Zimmer Biomet Stock Analysis - MarketRank™

Zimmer Biomet scored higher than 99% of companies evaluated by MarketBeat, and ranked 22nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Zimmer Biomet has received a consensus rating of Hold. The company's average rating score is 2.35, and is based on 9 buy ratings, 9 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Zimmer Biomet has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 7.91%

Earnings Growth

Earnings for Zimmer Biomet are expected to grow by 7.91% in the coming year, from $8.22 to $8.87 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zimmer Biomet is 20.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.72.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zimmer Biomet is 20.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.58.

Price to Earnings Growth Ratio

Zimmer Biomet has a PEG Ratio of 2.17. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Zimmer Biomet has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.16% of the float of Zimmer Biomet has been sold short.

Short Interest Ratio / Days to Cover

Zimmer Biomet has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Zimmer Biomet has recently decreased by 99.78%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Zimmer Biomet pays a meaningful dividend of 1.02%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Zimmer Biomet does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Zimmer Biomet is 21.24%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Zimmer Biomet will have a dividend payout ratio of 10.82% next year. This indicates that Zimmer Biomet will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -1.33

Percentage of Shares Shorted

0.16% of the float of Zimmer Biomet has been sold short.

Short Interest Ratio / Days to Cover

Zimmer Biomet has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Zimmer Biomet has recently decreased by 99.78%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.65

News Sentiment

Zimmer Biomet has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Zimmer Biomet this week, compared to 15 articles on an average week.

Search Interest

8 people have searched for ZBH on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.

MarketBeat Follows

5 people have added Zimmer Biomet to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Zimmer Biomet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $95,000.00 in company stock.

Percentage Held by Insiders

Only 0.70% of the stock of Zimmer Biomet is held by insiders.

Percentage Held by Institutions

88.89% of the stock of Zimmer Biomet is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ZBH Stock Analysis - Frequently Asked Questions

How have ZBH shares performed this year?

Zimmer Biomet's stock was trading at $105.63 at the start of the year. Since then, ZBH shares have decreased by 11.0% and is now trading at $93.99.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) issued its quarterly earnings results on Monday, May, 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The business's revenue was up 1.1% on a year-over-year basis.
Read the conference call transcript.

Does Zimmer Biomet have any subsidiaries?

The following companies are subsidiaries of Zimmer Biomet: Respondwell, Clinical Graphics, CD Diagnostics, Medtech SAS, Compression Therapy Products, LDR Holding, Cayenne Medical, and more.

Who are Zimmer Biomet's major shareholders?

Top institutional shareholders of Zimmer Biomet include Douglas Lane & Associates LLC (0.20%), Gradient Investments LLC (0.09%), QSM Asset Management Ltd (0.06%) and Thomasville National Bank (0.05%). Insiders that own company stock include Chad F Phipps, Sang Yi, Lori Winkler, Robert Hagemann, Michael W Michelson, Sreelakshmi Kolli and Betsy J Bernard.
View institutional ownership trends.

How do I buy shares of Zimmer Biomet?

Shares of ZBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zimmer Biomet own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zimmer Biomet investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM).

Company Calendar

• Record date for 4/30 Dividend: 3/31/2025
• Ex-Dividend for 4/30 Dividend: 3/31/2025
• Dividend Payable: 4/30/2025
• Last Earnings: 5/05/2025
• Record date for 7/31 Dividend: 6/26/2025
• Ex-Dividend for 7/31 Dividend: 6/26/2025
• Today: 7/16/2025
• Dividend Payable: 7/31/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:ZBH
• Previous Symbol: NYSE:ZMH
• CIK: 1136869
• Web: www.zimmerbiomet.com
• Phone: (574) 267-6131
• Fax: 574-372-4988
• Employees: 17,000
• Year Founded: 1927

Price Target and Rating

• Average Price Target for Zimmer Biomet: $111.39
• High Price Target: $135.00
• Low Price Target: $95.00
• Potential Upside/Downside: +18.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.35
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.52
• Trailing P/E Ratio: 20.79
• Forward P/E Ratio: 11.43
• P/E Growth: 2.17
• Net Income: $903.70 million
• Net Margins: 11.86%
• Pretax Margin: 13.65%
• Return on Equity: 12.73%
• Return on Assets: 7.34%

Debt

• Debt-to-Equity Ratio: 0.53
• Current Ratio: 2.44
• Quick Ratio: 1.46

Sales & Book Value

• Annual Sales: $7.68 billion
• Price / Sales: 2.42
• Cash Flow: $13.22 per share
• Price / Cash Flow: 7.11
• Book Value: $62.67 per share
• Price / Book: 1.50

Miscellaneous

• Outstanding Shares: 197,850,000
• Free Float: 196,463,000
• Market Cap: $18.60 billion
• Optionable: Optionable
• Beta: 0.71